A double-blind randomized controlled trial to assess efficacy of bromocriptine in cirrhotic patients with hepatic parkinsonism.

Amrish SahneyBarjesh Chander SharmaAnkur JindalLovkesh AnandVinod AroraRajan VijayaraghavanRavinder Mohan DhamijaGuresh KumarAnkit BhardwajShiv Kumar Sarin

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

Hepatic parkinsonism is seen in ~5% cirrhotics. Bromocriptine is a safe and effective therapy for these patients and is more effective in mild to moderate hepatic parkinsonism.

Keyphrases

randomized controlled trial
parkinson disease
end stage renal disease
drug induced
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
systematic review